$0.08
(Market cap
$65 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
3.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-5.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.7
-
Face value
--
-
Shares outstanding
27,753,789
9 Years Aggregate
CFO
$-80.65 Mln
EBITDA
$-124.20 Mln
Net Profit
$-123.83 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
INmune Bio (INMB)
| 50.6 | 27.0 | 78.0 | 19.3 | -34.5 | -38.4 | -- |
|
BSE Sensex
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
INmune Bio (INMB)
| -66.6 | -58.2 | 77.6 | -37.8 | -40.8 | 196.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
INmune Bio (INMB)
|
2.4 | 64.7 | 0.0 | -18.4 | -- | -83.9 | -- | 3.3 |
| 84.8 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 268.4 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 72.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.0 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 110.2 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 355.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 118.2 | 9,718.7 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.6 | |
| 541.4 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 592.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 |
Shareholding Pattern
View DetailsAbout INmune Bio (INMB)
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic... malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida. Read more
-
Co-Founder, President, CEO, Chief Medical Officer & Chairman
Dr. Raymond Joseph Tesi M.D.
-
Co-Founder, President, CEO, Chief Medical Officer & Chairman
Dr. Raymond Joseph Tesi M.D.
-
Headquarters
Boca Raton, FL
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for INmune Bio (INMB)
What is the current share price of INmune Bio Inc (INMB) Today?
The share price of INmune Bio Inc (INMB) is $2.35 (NASDAQ) as of 04-Sep-2026 13:36 EDT. INmune Bio Inc (INMB) has given a return of -34.48% in the last 3 years.
What is the current PB & PE ratio of INmune Bio Inc (INMB)?
Since, TTM earnings of INmune Bio Inc (INMB) is negative, P/E ratio is not available.
The P/B ratio of INmune Bio Inc (INMB) is 3.28 times as on 28-Aug-2026, a 37 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.90 |
1.76 |
2024 |
-2.47 |
3.24 |
2023 |
-6.74 |
5.30 |
2022 |
-3.97 |
1.89 |
2021 |
-5.83 |
2.20 |
What is the 52 Week High and Low of INmune Bio Inc (INMB)?
The 52-week high and low of INmune Bio Inc (INMB) are Rs 2.50 and Rs 1.09 as of 05-Sep-2026.
What is the market cap of INmune Bio Inc (INMB)?
INmune Bio Inc (INMB) has a market capitalisation of $ 65 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in INmune Bio Inc (INMB)?
Before investing in INmune Bio Inc (INMB), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.